Physician profile
Jim E Daulton
NPI 1538717319
$7,252.87
in general payments reported to CMS, 2019-2025
27 companies · $5,009 in 2025
The $5,009 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $30.00 · 2024: $2,214 · 2025: $5,009.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,403 · Travel and Lodging: $1,801 · Education: $19.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,402.55 |
| Travel and Lodging | $1,801.07 |
| Education | $19.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $2,036.04 | 2025 | |
| Abbvie INC. | $1,047.14 | 2024-2025 | |
| Amgen INC. | $867.12 | 2024-2025 | Krystexxa, Enbrel, Otezla |
| Ucb, INC. | $744.13 | 2024-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $406.37 | 2024-2025 | |
| Janssen Biotech, INC. | $342.61 | 2024-2025 | Tremfya |
| Ani Pharmaceuticals, INC. | $309.03 | 2024-2025 | Purified Cortrophin Gel |
| Fresenius Kabi USA, LLC | $297.03 | 2024-2025 | Tyenne |
| Octapharma USA, INC. | $182.43 | 2024-2025 | Octagam Immune Globulin (Human) |
| Mallinckrodt Hospital Products INC. | $167.76 | 2024-2025 | Acthar |
| Lilly USA, LLC | $155.08 | 2024-2025 | Taltz, Zepbound |
| Radius Health, INC. | $111.68 | 2025 | Tymlos |
| Astrazeneca Pharmaceuticals LP | $82.19 | 2024-2025 | Saphnelo |
| Alexion Pharmaceuticals, INC. | $69.66 | 2024-2025 | Strensiq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.73 | 2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $45.81 | 2024-2025 | Orencia |
| Genzyme Corporation | $42.31 | 2024-2025 | |
| Sobi, INC | $41.71 | 2025 | |
| Organon LLC | $37.00 | 2024-2025 | Hadlima |
| Boston Scientific Corporation | $34.61 | 2024 | |
| Kiniksa Pharmaceuticals International, Plc | $30.02 | 2024 | Arcalyst |
| Heron Therapeutics, INC. | $30.00 | 2022 | |
| Kyowa Kirin, INC. | $27.14 | 2024 | Crysvita |
| Actelion Pharmaceuticals US, INC. | $25.50 | 2024 | Opsumit, Uptravi |
| Genentech USA, INC. | $21.42 | 2024 | Actemra |
| Teva Pharmaceuticals USA, INC. | $19.14 | 2024 | Truxima |
| Fidia Pharma USA INC. | $18.21 | 2024 | Hymovis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jim Daulton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.